Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhFSH-CTP + hCG to initiate or restore puberty in adolescent males with idiopathic hypogonadotropic hypogonadism
CTR20243077Phase 3Active
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of corifollitropin alfa in Congenital Hypogonadotropic Hypogonadism (CHH), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Started Oct 2024; status: active.
02
Drugs
corifollitropin alfa
03
Conditions
Congenital Hypogonadotropic Hypogonadism (CHH)
Beyond the preview
Go deeper on CTR20243077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243077.